These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 6247892

  • 1. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR.
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract] [Full Text] [Related]

  • 2. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
    Carter AJ, Heptinstall S.
    Thromb Haemost; 1985 Oct 30; 54(3):612-6. PubMed ID: 3937261
    [Abstract] [Full Text] [Related]

  • 3. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F, Beetens J, de Chaffoy de Courcelles D, Vercammen E, Freyne E, Janssen PA.
    Prog Clin Biol Res; 1989 Oct 30; 301():567-72. PubMed ID: 2529556
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
    Fitzpatrick FA, Gorman RR.
    Biochim Biophys Acta; 1978 Mar 01; 539(2):162-72. PubMed ID: 629996
    [Abstract] [Full Text] [Related]

  • 5. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L, Marcinkiewicz E.
    Pharmacol Res Commun; 1979 Feb 01; 11(2):133-46. PubMed ID: 375247
    [No Abstract] [Full Text] [Related]

  • 6. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR.
    Fed Proc; 1979 Jan 01; 38(1):83-8. PubMed ID: 215465
    [No Abstract] [Full Text] [Related]

  • 7. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR, Fitzpatrick FA, Miller OV.
    Biochem Biophys Res Commun; 1977 Nov 07; 79(1):305-13. PubMed ID: 200243
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of thromboxane receptors in human platelets.
    Jones RL, Wilson NH, Armstrong RA.
    Adv Exp Med Biol; 1985 Nov 07; 192():67-81. PubMed ID: 3010674
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Requirement of ADP for arachidonic acid-induced platelet aggregation: studies with selective thromboxane-synthase inhibitors.
    Cerletti C, Minoldo S, Bucchi F, Del Maschio A, de Gaetano G.
    Biochem Pharmacol; 1986 Apr 01; 35(7):1201-3. PubMed ID: 3083818
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of 2-indolecarbohydrazides on thromboxane synthetase activity and on in vitro and ex vivo blood platelet aggregation. New selective inhibitors.
    Monge A, Erro A, Parrado P, Font M, Aldana I, Rocha E, Fernandez-Alvarez E.
    Arzneimittelforschung; 1986 Aug 01; 36(8):1184-6. PubMed ID: 3096343
    [Abstract] [Full Text] [Related]

  • 14. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
    Sprague PW, Heikes JE, Harris DN, Greenberg R.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Aug 01; 11():337-43. PubMed ID: 6303073
    [No Abstract] [Full Text] [Related]

  • 15. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins.
    MacIntyre DE, Gordon JL.
    Thromb Res; 1977 Dec 01; 11(6):705-13. PubMed ID: 203057
    [No Abstract] [Full Text] [Related]

  • 16. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
    Varfolomeev SD, Lakin KM, Mevkh AT, Novikova NV, Rukazenkov IuZ.
    Dokl Akad Nauk SSSR; 1985 Dec 01; 282(1):194-6. PubMed ID: 3928305
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S, Wakitani K, Katsube N, Kawasaki A, Tsuboshima M, Naito J, Ujiie A, Komatsu H, Iizuka K.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Dec 01; 11():241-4. PubMed ID: 6221530
    [No Abstract] [Full Text] [Related]

  • 18. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W, Roth P, Weber PC.
    Thromb Haemost; 1981 Jun 30; 45(3):204-7. PubMed ID: 7025338
    [Abstract] [Full Text] [Related]

  • 19. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
    Harris DN, Phillips MB, Michel IM, Goldenberg HJ, Heikes JE, Sprague PW, Antonaccio MJ.
    Prostaglandins; 1981 Aug 30; 22(2):295-307. PubMed ID: 6270744
    [Abstract] [Full Text] [Related]

  • 20. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1984 Jan 30; 228(1):240-4. PubMed ID: 6319669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.